查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球心臟生物标誌物市场-2022-2029
市场调查报告书
商品编码
1146419

全球心臟生物标誌物市场-2022-2029

Global Cardiac Biomarkers Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期间（2022-2029 年），心臟生物标誌物的市场规模预计将以 10.5% 的复合年增长率增长。

心臟生物标誌物是心臟受损或受压时释放到血液中的生物分子。此类生物标誌物的识别和估计有助于诊断急性冠状动脉症候群 (ACS)、心臟缺血或其他与心臟血流受损相关的疾病。

市场动态

不断上升的心脏病人口、人口老龄化和市场开发正在推动全球心臟生物标誌物市场的增长。

心血管疾病发病率的上升和老年人口的增加正在推动全球心臟生物标誌物市场的增长。

由于心血管疾病病例的增加，预计市场在预测期内将扩大。根据英国心臟基金会的数据，2020 年将有超过 168,319 人死于心血管疾病。由于世界上老年人口的增加和现代生活方式的采用，心血管病例的数量正在增加。根据世界卫生组织数据，2020年60岁及以上人口将超过10亿，预计到2050年将达到21亿。此外，烟草每年在全世界造成 800 万人死亡。在这 800 万人中，约 700 万人是由于直接使用烟草造成的，约 120 万人是由于非吸烟者接触二手烟造成的。因此，从上述数据来看，心血管病例和老年人口的增加预计将推动全球心血管生物标誌物市场的增长。

缺乏特异性以及对更灵敏的心臟生物标誌物分析系统的需求阻碍了全球心臟生物标誌物市场的增长。

然而，对非特异性和更敏感的心臟生物标誌物分析系统的需求是限制全球心臟生物标誌物市场增长的一个因素。根据美国临床化学协会 (AACC) 的说法，将心臟生物标誌物用作即时检测 (POCT) 需要高度敏感的诊断工具，因为 POCT 无法区分肌钙蛋白等低水平的心臟生物标誌物。这是。此外，由于肌钙蛋白浓度升高需要几个小时，因此在需要快速决策的情况下不能采用这种诊断方法。

COVID-19 的影响

由于在大流行期间增加使用心臟生物标誌物以降低患心脏病的风险，COVID-19 大流行对全球心臟生物标誌物市场产生了积极影响。根据 NCBI，在 2021 年，复杂的 COVID-19 病例显示与不良疾病结果相关的心臟生物标誌物升高。因此，在大流行期间，心臟生物标誌物的销售额相对于严重的 COVID-19 病例有所上升，这对全球心臟生物标誌物市场产生了积极影响。

细分分析

预计在预测期间（2022-2029 年），床旁检测的需求量很大。

预计在预测期内（2022-2029 年），床旁检测将主导全球心臟生物标誌物市场。即时检测是在患者处或附近进行的检测。重要的是，这是在实验室之外进行的测试。与传统实验室测试相比，即时测试可以在更短的时间内完成，并对患者护理产生直接影响。床旁检测通过为医生提供有关患者状况的即时详细资讯，改善了患者的体验，提供更高质量的护理。

即时检测的优势正在推动其在全球心臟生物标誌物市场的主导地位。例如，即时结果可增强临床工作流程并提供运营和财务收益。与传统的实验室测试相比，即时检测对患者来说更方便，并提高了患者的满意度。此外，医疗点支持对有心血管疾病 (CVD) 风险的人进行健康检查，增加患者检测并有助于降低心血管死亡率。根据世界卫生组织 (WHO) 的数据，心脏病发作和中风导致的过早死亡中有 80% 是可以预防的。总之，在预测期内，护理点预计将主导全球心臟生物标誌物市场。

区域分析

预计全球心臟生物标誌物市场将由北美主导。

北美主导着全球心臟生物标誌物市场。据评估，它在预测期内（2022-2029 年）将保持巨大的市场规模。例如，根据 CDC 的数据，到 2020 年，每 34 秒就有一名美国人死于心血管疾病，导致超过 697,000 人死亡。此外，Abbott Laboratories、Beckman Coulter、Roche Diagnostics Ltd.、Becton Dickinson & Company、Bio-Rad Laboratories、Thermo Fisher Scientific 等大多数主要市场参与者都在场，在全球心臟生物标誌物市场占有很大份额通过各种市场策略，总部位于美国，这确保了北美在全球心臟生物标誌物市场的主导地位。例如，2021 年 4 月，罗氏（Roche）宣布了两个关键心臟生物标誌物的新系列生物标誌物，即高敏心肌肌钙蛋白 T（cTnT-hs）和 N 端脑利钠□前体测试（NT-proBNP），使用 Elecsys技术。提出了所需的应用。同样在 2021 年 7 月，Beckman Coulter 与 Quidel Corporation 签订了最终协议，以获取製造、分销和销售用于 Beckman Coulter 分析仪的 BNP 检测的所有权利。

竞争格局

Thermo Fisher 是一家美国公司，成立于 1956 年。它拥有 Thermo Scientific、Applied Biosystems、Invitrogen、Fisher Scientific、Unity Lab Services、Patheon 和 PPD 等行业领先品牌，是科学服务领域的全球领导者，年收入约为 400 亿美元。

产品组合

Thermo Fisher 的心臟生物标誌物产品组合包括 Thermo Scientific MAS CardioImmune XL Controls。 Thermo Scientific MAS CardioImmune XL Controls：即用型液体测量多分析物对照品，用于监测血清心臟标誌物测定。这些质控品也以合适的 Vista 小瓶形式提供。

全球心臟生物标誌物市场报告提供对 40 多个 市场数据表、45 多个图表和 200 页（大约）的访问。

内容

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 促进因素
      • 心脑血管疾病增加
      • 老年人口增加
    • 抑制因素
      • 缺乏特异性
      • 需要更灵敏的心臟生物标誌物分析系统
      • 严格的规定
    • 商机
    • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章心臟生物标誌物测试

  • 肌钙蛋白（I 或 T）
  • 肌酸激□ (CK)
  • 肌红蛋白
  • 半乳糖凝集素3
  • HS-CRP
  • BNP（或 NT-proBNP）

第 8 章适应症

  • 急性冠状动脉症候群
  • 充血性心力衰竭
  • 心肌梗塞 (MI)
  • 心绞痛
  • 其他

第 9 章最终用户

  • 实验室检查
  • 即时检测

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章公司简介

  • Thermo Fisher Scientific
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Abbott Laboratories
  • Beckman Coulter
  • Roche Diagnostics Corporation
  • Becton Dickinson And Co.
  • Bio-Rad Laboratories
  • BioMerieux
  • Siemens Healthcare
  • LumiraDx
  • Randox laboratories

第 13 章 DataM

简介目录
Product Code: DMCD256

Market Overview

Cardiac Biomarkers Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 10.5% during the forecast period (2022-2029).

Cardiac biomarkers are biological molecules released into the blood as the heart is damaged or under stress. Identifying and estimating such biomarkers help diagnose acute coronary syndrome (ACS) and cardiac ischemia or other conditions associated with impaired blood flow to the heart.

Market Dynamics

The rising heart disease cases, growing geriatric population and market developments fuel the growth of the global cardiac biomarkers market.

The growing incidences of cardiovascular disease and the geriatric population propel the global cardiac biomarkers market growth.

The growing cases of cardiovascular diseases are anticipated to expand the market over the forecast period. According to the British Heart Foundation, in 2020, over 168,319 deaths were caused by cardiovascular diseases. Since the global geriatric population is growing at an increased rate, and the adoption of modern lifestyles are contributing factors to the growing incidences of cardiovascular cases. According to the world health organization data, in 2020, over 1 billion people were aged 60 and above, which is predicted to be 2.1 billion by 2050. Furthermore, annually 8 million people are dead due to tobacco consumption worldwide. Out of these 8 million, about 7 million are due to the direct use of tobacco, and around 1.2 million are because non-smokers are exposed to secondhand smoke. Thus, with the data mentioned earlier, the growing cardiovascular cases and geriatric population will drive the global cardiovascular biomarkers market growth.

The absence of specificity and the necessity of a more sensitive cardiac biomarker analysis system hinder the global cardiac biomarkers market growth.

However, the absence of specificity and the necessity of a more sensitive cardiac biomarker analysis system is a major restraint for the global cardiac biomarker market growth. According to American Association for Clinical Chemistry (AACC), using cardiac biomarkers as point-of-care testing (POCT) needs a high-sensitivity diagnostic tool since POCT cannot identify low levels of a cardiac biomarker such as troponin. Since it takes several hours to increase troponin levels for the system to detect, such a diagnostic method cannot be employed in rapid decision-requiring situations.

COVID-19 Impact

There was a positive impact of the COVID-19 pandemic on the global cardiac biomarker market since the use of cardiac biomarkers increased during the pandemic to reduce the risk of cardiac diseases. According to the NCBI, in 2021, complicated cases of COVID-19 exhibited raised cardiac biomarkers associated with adverse disease outcomes. Therefore, the sales of cardiac biomarkers were elevated for severe COVID-19 cases during the pandemic, positively impacting the global cardiac biomarker market.

Segment Analysis

Point-of-care testing is predicted to have a high demand during the forecast period (2022-2029).

Point-of-care testing is expected to dominate the global cardiac biomarkers market during the forecast period (2022-2029). Point-of-care testing is a test conducted at or near the site of the patient. Importantly it is a laboratory test performed outside of the laboratory setting. Point-of-care testing gives a quicker completion time than traditional laboratory testing, with the potential for immediate impact on patient care. Point-of-care testing enhances patient experience with a higher quality of care via delivering rapid details to the physicians regarding the patient's condition.

The benefits offered by point-of-care testing fuel this segment's dominance over the global cardiac biomarkers market. For instance, the results are available immediately and practice workflow is enhanced, resulting in operational and economic benefits. Point-of-care testing is more convenient than conventional laboratory testing for patients, which has improved patient satisfaction. Furthermore, point of care can support health screenings in those at risk of cardiovascular disease (CVD) and enhance patient adherence with testing frequency, benefitting in reducing cardiovascular mortality. Since 80% of premature deaths from heart attack and stroke are avoidable, as per the World Health Organization. Thus, from the data mentioned, it is anticipated that the point of care will dominate the global cardiac biomarkers market throughout the forecast period.

Geographical Analysis

North America is predicted to command the global Cardiac Biomarkers market.

North America dominated the global cardiac biomarkers market. It is evaluated to hold a significant market size over the forecast period (2022-2029). As there are a high number of cardiovascular cases, for example, according to the CDC, in 2020, a U.S. American died every 34 seconds of cardiovascular disease, causing over 697,000 deaths. Furthermore, the presence of most of the key market players like Abbott Laboratories, Beckman Coulter, Roche Diagnostics Corporation, Becton Dickinson And Co., Bio-Rad Laboratories, and Thermo Fisher Scientific, holding a large share of the global cardiac biomarkers market through various market tactics are based in the United States ensuring the dominance of North America over the global cardiac biomarkers market. For instance, in April 2021, Roche introduced a series of five new intended applications for two key cardiac biomarkers using the Elecsys technology, a high-sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). Also, in JULY 2021, Beckman Coulter formed a definitive agreement with Quidel Corporation to obtain all rights associated with the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers.

Competitive Landscape

The major players operating in the global Cardiac Biomarkers market are Abbott Laboratories, Beckman Coulter, Roche Diagnostics Corporation, Becton Dickinson and Co., Bio-Rad Laboratories, BioMerieux, Siemens Healthcare, LumiraDx, Randox laboratories and Thermo Fisher Scientific. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the cardiac biomarkers market globally. For instance, in June 2022, LumiraDx Limited diversified its portfolio with CE Mark for its D-Dimer and NT-proBNP tests.

Thermo Fisher.

Overview:

Thermo Fisher is a U.S.-based company founded in 1956. It is the world leader in serving science with annual revenue of approx. $40 billion has industry-leading brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.

Product Portfolio:

The product portfolio of Thermo Fisher for cardiac biomarkers contains Thermo Scientific MAS CardioImmune XL Controls: Monitor serum cardiac marker test methods with ready-to-use, liquid-assayed multi-analyte Thermo Scientific MAS CardioImmune XL Controls. These controls are also available in a suitable Vista vial format.

The global cardiac biomarkers market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Cases of Cardio-vascular diseases
      • 4.1.1.2. Growing Geriatric Population
    • 4.1.2. Restraints
      • 4.1.2.1. Absence of Specificity
      • 4.1.2.2. The Necessity of a More Sensitive Cardiac Biomarker Analysis System
      • 4.1.2.3. Stringent Regulation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Cardiac Biomarker Tests

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 7.1.2. Market Attractiveness Index, By Cardiac Biomarker Tests
  • 7.2. Troponin (I or T)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Creatine kinase (CK)
  • 7.4. Myoglobin
  • 7.5. Galectin-3
  • 7.6. HS-CRP
  • 7.7. BNP (or NT-proBNP)

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Acute Coronary Syndrome
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Congestive Heart Failure
  • 8.4. Myocardial infarction (MI)
  • 8.5. Angina
  • 8.6. Other

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Laboratory Testing
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Point of Care Testing

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cardiac Biomarker Tests
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Thermo Fisher Scientific
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Abbott Laboratories
  • 12.3. Beckman Coulter
  • 12.4. Roche Diagnostics Corporation
  • 12.5. Becton Dickinson And Co.
  • 12.6. Bio-Rad Laboratories
  • 12.7. BioMerieux
  • 12.8. Siemens Healthcare
  • 12.9. LumiraDx
  • 12.10. Randox laboratories

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us